Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
NIHR annual report for 2024/25 has been published today, showcasing the impact of NIHR funded and supported research.
Hear from CEO @Lucy Chappell and find out about some of the ways NIHR research is:
changing lives
improving quality of…
A new wearable wristband could transform diabetes management by continuously tracking not just glucose, but also chemical and cardiovascular signals that affect disease progression and overall health. The technology was recently reported in Nature Biomedical Engineering.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us